On March 6, 2017, the PTAB issued a pair of final written decisions upholding the patentability of U.S. Patent Nos. 7,932,268 (IPR2015-01836) and 8,618,135 (IPR2015-01835), in challenges filed by the Coalition for Affordable Drugs VIII, LLC (CFAD). The patents are owned by the University of Pennsylvania, and are licensed to Aegerion Pharmaceuticals, Inc. (a subsidiary of Novelion Therapeutics Inc.). Both patents relate to methods for using lomitapide, an MTP inhibitor, in the treatment of hyperlipidemia and/or hypercholesterolemia. Aegerion markets a lomitapide product under the name "JUXTAPID®."
Read the full article at ptablitigationblog.com.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
